Abstract
Two apparently independent mechanisms of instability are recognized in colorectal cancer, microsatellite instability and chromosomal instability. Evidence from colorectal cancer cell lines indicates the presence of either, or both, types of instability in the vast majority. Here, we sought to determine the prevalence of such instability in primary sporadic colorectal cancers. Microsatellite instability was established by demonstration of ovel clonal, nongerm-line alleles in at least two of four tested loci. Chromosomal abnormalities were identified by comparative genomic hybridization (CGH) and flow cytometric analysis of nuclear DNA content. Tumours harbouring chromosomal instability were distinguished from those with stable but aneuploid karyotypes by comparing chromosomal defects at multiple sites throughout each cancer. This analysis allowed assessment of both the number of chromosomal abnormalities and their heterogeneity throughout the tumour. The results confirm that microsatellite instability is consistently associated with multiple, repeated changes in microsatellites throughout the growth of the affected colorectal carcinomas. There were also several carcinomas in which major structural or numerical abnormalities in chromosomes had clearly continued to arise during tumour growth. However, a substantial subset of tumours showed neither microsatellite instability nor multiple, major chromosomal abnormalities. We suggest that the development of a proportion of colorectal cancers proceeds via a different pathway of carcinogenesis not associated with either of the currently recognized forms of genomic instability.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, Jarvinen H, Powell SM, Jen J, Hamilton SR, Petersen GM, Kinzler KW, Vogelstein B and de la Chapelle A. . 1993 Science 260: 812–816.
Aaltonen LA, Peltomaki P, Mecklin JP, Jarvinen H, Jass JR, Green JS, Lynch HT, Watson P, Tallqvist G, Juhola M, Sistonen P, Hamilton SR, Kinzler KW, Vogelstein B and de la Chapelle A. . 1994 Cancer Res. 54: 1645–1648.
Akiyama Y, Sato H, Yamada T, Nagasaki H, Tsuchiya A, Abe R and Yuasa Y. . 1997 Cancer Res. 57: 3920–3923.
Borresen AL, Lothe RA, Meling GI, Lystad S, Morrison P, Lipford J, Kane MF, Rognum TO and Kolodner RD. . 1995 Hum. Mol. Gen. 4: 2065–2072.
Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, Kane M, Erabino C, Lipford J, Lindblom A, Tannergard P, Bollag RJ, Godwin AR, Ward DC, Nordenskjold M, Fishel R, Kolodner R and Liskay RM. . 1994 Nature 368: 258–261.
Bubb VJ, Curtis LJ, Cunningham C, Dunlop MG, Carothers AD, Morris RG, White S, Bird CC and Wyllie AH. . 1996 Oncogene 12: 2641–2649.
Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JKV, Markowitz SD, Kinzler KW and Vogelstein B. . 1998 Nature 392: 300–303.
Carder PJ, Cripps KJ, Morris R, Collins S, White S, Bird CC and Wyllie AH. . 1995 Br. J. Cancer 71: 215–218.
Carder P, Wyllie AH, Purdie CA, Morris RG, White S, Piris J and Bird CC. . 1993 Oncogene 8: 1397–1401.
Eshleman JR, Casey G, Kochera ME, Sedwick WD, Swinler SE, Veigl ML, Willson JKV, Schwartz S and Markowitz SD. . 1998 Oncogene 17: 719–725.
Eshleman JR, Lang EZ, Bowerfind GK, Parsons R, Vogelstein B, Willson JKV, Veigl ML, Sedwick WD and Markowitz SD. . 1995 Oncogene 10: 33–37.
Eshleman JR and Markowitz SD. . 1996 Hum. Mol. Gen. 5: 1489–1494.
Eshleman JR, Markowitz SD, Donover PS, Lang EZ, Lutterbaugh JD, Li GM, Longeley M, Modrich P, Veigl ML and Sedwick WD. . 1996 Oncogene 12: 1425–1432.
Goelz SE, Hamilton SR and Vogelstein B. . 1985 Biochem. Biophys. Res. Commun. 130: 118–126.
Gyapay G, Morissette J, Vignal A, Dib C, Fizames C, Millasseau P, Marc S, Bernardi G, Lathrop M and Weissenbach J. . 1994 Nature Genet. 7: 246–339.
Hartwell L. . 1992 Cell 71: 543–546.
Hoang JM, Cottu PH, Thuille B, Salmon RJ, Thomas G and Hamelin R. . 1997 Cancer Res. 57: 300–303.
Ionov Y, Peinado MA, Malkhosyan S, Shibata D and Perucho M. . 1993 Nature 363: 558–561.
Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F and Pinkel D. . 1992 Science 258: 818–821.
Kim HG, Jen J, Vogelstein B and Hamilton SR. . 1994 Am. J. Pathol. 145: 148–156.
Konishi M, Kikuchi-Yanoshita R, Tanaka K, Muraoka M, Onda A, Okumura Y, Kishi N, Iwama T, Mori T, Koike M, Ushio K, Chiba M, Nomizu S, Konishi F, Utsunomiya J and Miyaki M. . 1996 Gastroenterology 111: 307–317.
Lengauer C, Kinzler KW and Vogelstein B. . 1997 Nature 386: 623–627.
Levine AJ, Momand J and Finlay CA. . 1991 Nature 351: 453–456.
Liu B, Parsons R, Papadopoulos N, Nicolaides NC, Lynch HT, Watson P, Jass JR, Dunlop M, Wyllie A, Peltomaki P, de la Chapelle A, Hamilton SR, Vogelstein B and Kinzler KW. . 1996 Nature Med. 2: 169–174.
Loeb LA. . 1991 Cancer Res. 51: 3075–3079.
Lothe RA, Peltomaki P, Meling GI, Aaltonen LA, Nystrom-Lahti M, Pylkkanen L, Heimdal K, Andersen TI, Moller P, Rognum TO, Fossa SD, Haldorsen T, Langmark F, Brogger A, de la Chapelle A and Borresen AL. . 1993 Cancer Res. 53: 5849–5852.
Markowitz S, Wang J, Myeroff L, Parsons R, Sun LZ, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, Brattain M and Willson JKV. . 1995 Science 268: 1336–1338.
McQueen HA, Wyllie AH, Piris J, Foster E and Bird CC. . 1991 Br. J. Cancer 63: 94–96.
Miyaki M, Konishi M, Tanaka K, Kikuchi-Yanoshita R, Mutaoka M, Yasuno M, Igari T, Koike M, Chiba M and Mori T. . 1997 Nature Genet. 17: 271–272.
Nicolaides NC, Papadopoulos N, Liu B, Wei YF, Carter KC, Ruben SM, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM, Adams MD, Venter JC, Dunlop MG, Hamilton SR, Petersen GM, de la Chapelle A, Vogelstein B and Kinzler KW. . 1994 Nature 371: 75–80.
Nystrom-Lahti M, Parsons R, Sistonen P, Pylkkanen L, Aaltonen LA, Leach FS, Hamilton SR, Watson P, Bronson E, Cavalieri J, Lynch J, Lanspa S, Smyrk T, Lynch P, Drouhard T, Kinzler KW, Vogelstein B, Lynch HT, de la Chapelle A and Peltomaki P. . 1994 Am. J. Hum. Genet. 55: 659–665.
Papadopoulos N, Nicolaides NC, Wei YF, Ruben SM, Carter KC, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM, Adams MD, Venter JC, Hamilton SR, Petersen GM, Watson P, Lynch HT, Peltomaki P, Mecklin JP, de la Chapelle A, Kinzler KW and Vogelstein B. . 1994 Science 263: 1625–1629.
Peltomaki P, Lothe RA, Aaltonen LA, Pylkkanen L, Nystrom-Lahti M, Seruca R, David L, Holm R, Ryberg D, Haugen A, Brogger A, Borresen AL and de la Chapelle A. . 1993 Cancer Res. 53: 5853–5855.
Purdie CA, O’Grady J, Piris J, Wyllie AH and Bird CC. . 1991 Am. J. Pathol. 138: 807–813.
Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC and Perucho M. . 1997 Science 275: 967–969.
Senba S, Konishi F, Okamoto T, Kashiwagi H, Kanazawa K, Miyaki M, Konishi M and Tsukamoto T. . 1998 Cancer 82: 279–285.
Thibodeau SN, Bren G and Schaid D. . 1993 Science 260: 816–819.
Thibodeau SN, French AJ, Cunningham JM, Tester D, Burgart LJ, Roche PC, McDonnell SK, Schaid DJ, Vockley CW, Michels VV, Farr Jr GH and O’Connell MJ. . 1998 Cancer Res. 58: 1713–1718.
Togo G, Toda N, Kanai F, Kato N, Shiratori Y, Kishi K, Imazeki F, Makuuchi M and Omata M. . 1996 Cancer Res. 56: 5620–5623.
Vindelov LL, Christensen IJ and Nissen NI. . 1983 Cytometry 3: 323–327.
Wijnen J, Vasen H, Khan PM, Menko FH, van der Klift H, van Leeuwen C, van den Broek M, van Leeuwen-Cornelisse I, Nagengast F, Meijers-Heijboer A, Lindhout D, Griffioen G, Cats A, Kleibeuker J, Varesco L, Bertario L, Bisgaard ML, Mohr J and Fodde R. . 1995 Am. J. Hum. Genet. 56: 1060–1066.
Wu C, Akiyama Y, Imai K, Miyake S, Nagasaki H, Oto M, Okabe S, Iwama T, Mitamura K, Masumitsu H, Nomizu T, Baba S, Maruyama K and Yuasa Y. . 1994 Oncogene 9: 991–994.
Yao J, Eu KW, Seow-Choen F, Vijayan V and Cheah PY. . 1999 Int. J. Cancer 80: 667–670.
Acknowledgements
We are grateful to Harris Morrison of the Human Genetics Unit, MRC, Edinburgh for help and advice with CGH and to Joan Flanigan and Jennifer Doig for expert technical assistance. This study was funded by a Programme Grant from the Cancer Research Campaign [CRC] (Ref. no. 18201), the Medical Research Council and the Dr James and Bozena Bain fund.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Georgiades, I., Curtis, L., Morris, R. et al. Heterogeneity studies identify a subset of sporadic colorectal cancers without evidence for chromosomal or microsatellite instability. Oncogene 18, 7933–7940 (1999). https://doi.org/10.1038/sj.onc.1203368
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203368
Keywords
This article is cited by
-
Li–Fraumeni syndrome heterogeneity
Clinical and Translational Oncology (2020)
-
Copy number alterations and allelic ratio in relation to recurrence of rectal cancer
BMC Genomics (2015)
-
Competing views on cancer
Journal of Biosciences (2014)
-
Molecular Origins of Colon and Rectal Cancer: Not a Wnt–Wnt Situation
Current Colorectal Cancer Reports (2013)
-
Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations
American Journal of Gastroenterology (2013)